Levetiracetam
Product Images NDC 53808-1042

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 53808-1042). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image For 500mg (500mg Trigen)

This is a prescription medication called Levetiracetam, available in 500mg tablets. The package contains 30 tablets and the Lot number is 212301A for Trigen. The medication was packaged by the Department of Health Central Pharmacy in Tallahassee, FL, and the expiration date is 03102014.*

FDA Label Image

Chemical Structure (Levetiracetam 01)

FDA Label Image

Figure 1 (Levetiracetam 02)

The text describes a chart that displays the percentage of patients taking the drug Levetiracetam at different dosages (1000mg/day and 3000mg/day) compared to a control group taking placebo. The chart also includes percentages ranging from 0% to 45%. The last line of the text shows a value of 396%, which may be a formatting error.*

FDA Label Image

Figure 2 (Levetiracetam 03)

This is a chart or table displaying the percentage of patients in a study who were given a placebo (N=111) or different doses of levetiracetam (1000mg/day for N=106 or 2000mg/day for N=105). The percentages represent the proportion of patients in each group. However, the "% of Patients" title suggests that there may be more information in the table that is not visible in the text provided.*

FDA Label Image

Figure 3 (Levetiracetam 04)

This data table appears to show the percentage change in some variable for patients taking either a placebo or the drug Levetiracetam at a dose of 3000mg/day. However, without more context or information it is difficult to determine what the variable being measured is or the significance of the percentage changes.*

FDA Label Image

Figure 4 (Levetiracetam 05)

This appears to be a graph showing the percentage of patients who were given either a placebo or Levetiracetam and the percentage of patients who experienced a certain outcome. 19.6% of patients who received the placebo experienced the outcome, while 44.6% of patients who received Levetiracetam experienced the outcome. However, without additional context or information regarding the outcome, it is unclear what the significance of these percentages is.*

FDA Label Image

Figure 5 (Levetiracetam 06)

FDA Label Image

Logo (Levetiracetam 07)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.